|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||35.87 - 36.73|
|52-week range||21.76 - 36.73|
|Beta (5Y monthly)||0.48|
|PE ratio (TTM)||146.92|
|Forward dividend & yield||0.24 (0.65%)|
|Ex-dividend date||30 Mar 2023|
|1y target est||N/A|
AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study.
The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.
An analyst had a fresh new take on the company's prospects, and it wasn't all that positive.